Chronic Lung Disease of Prematurity
14
2
3
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
14.3%
2 terminated out of 14 trials
75.0%
-11.5% vs benchmark
14%
2 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Duodenal Feeds in Very Low Birth Weight Infants
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
PAL to Improve Oral Feeding for Infants With Chronic Lung Disease
Relationship Between EIT and Respiratory Status in Very Preterm Infants
Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease
Reversibility of Bronchial Obstruction in Children Born Preterm
BPD Saturation TARgeting
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
Continuous Versus Intermittent Bolus Feeding in Very Preterm Infants - Effect on Respiratory Morbidity
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
Safe Use of Speaking Valve in Children During Sleep Using Trans-tracheal Pressure Measurement
Prevention of Chronic Lung Disease (CLD) in Preterm Infants